Jefferies Global Healthcare Conference
Logotype for Aclaris Therapeutics Inc

Aclaris Therapeutics (ACRS) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Aclaris Therapeutics Inc

Jefferies Global Healthcare Conference summary

16 Nov, 2026

Pipeline updates and priorities

  • Bosakitug, a TSLP monoclonal antibody, missed the atopic dermatitis endpoint; the small study showed robust Th1, Th17 and Th2 pharmacodynamic responses, while single-agent TSLP was not part of the base plan.

  • Modzatinib 2138’s oral lichen planus study started last week and will cover mucosal, cutaneous and scalp phenotypes.

  • The 9494 next-generation ITK program completed required toxicology; filing is planned in the coming weeks, followed by SAD/MAD studies and proof of concept in 2027.

  • 9494 is being developed for TH2-based oral indications, potentially atopic disease or asthma; disease-related measures such as elevated FeNO may be included in MAD work.

  • A second indication for the 052 bispecific, either asthma or atopic dermatitis, is expected to be selected before year-end; designs may include a positive control or Dupixent failures.

052 bispecific and EoE strategy

  • EoE is now the lead indication for 052; tezepelumab’s positive data increased the rationale for a larger study focused initially on EoE.

  • KOLs cited rising EoE prevalence, potentially exceeding 1 million patients, and TSLP’s potential to address broader inflammatory pathways beyond eosinophils.

  • The EoE study is expected in 2027, with histologic, symptom and endoscopic outcomes; the aim is an efficient design that moves rapidly from phase 2 toward registration.

  • Target profile includes faster onset and greater depth or breadth of response; management also anticipates evaluating induction and maintenance approaches and longer dosing intervals.

Oral lichen planus study

  • The 2138 basket study starts with oral disease, then plans cutaneous and scalp cohorts; target enrollment is 35–40 patients, with interim analysis after ~60% reach week 16.

  • ODSS is the primary endpoint; IGA and patient-reported outcomes are also included. ODSS is a continuous 0–106 measure and was used to power the initial cohort.

  • After interim results, the plan is to consult the FDA on the registrational program; Fast Track designation enables further agency interaction.

  • Management cited ITK’s upstream mechanistic fit with T-cell receptor-driven disease and viewed an ODSS response near 50% as compelling.

  • A recent topical corticosteroid study in milder oral disease showed a 20% response rate; management noted the different disease severity and lower baseline ODSS scores.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Aclaris Therapeutics